|
A first-in-human dose phase 1 study of LY3009120 in advanced cancer patients. |
|
|
Stock and Other Ownership Interests - MolecularMatch; Oncorena |
Honoraria - Adaptimmune; Baxter; Bayer; Merrimack |
Consulting or Advisory Role - Baxter; Bayer |
Research Funding - Amgen; AstraZeneca; Daiichi Sankyo; Eisai; Genentech; Lilly; Merck; Mirati Therapeutics; miRNA Therapeutics; Novartis; Pfizer |
Travel, Accommodations, Expenses - Loxo; miRNA Therapeutics |
Other Relationship - Oncorena |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - Caremission; WCCT Global |
Consulting or Advisory Role - Castle Biosciences; Deciphera; RedHill Biopharma |
Research Funding - Abbvie (Inst); Amgen (Inst); Amgen (Inst); Array BioPharma (Inst); Calithera Biosciences (Inst); Celldex (Inst); Deciphera (Inst); Endocyte (Inst); ESSA (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Lilly (Inst); Lilly/ImClone (Inst); MedImmune (Inst); Merck Serono (Inst); Millennium (Inst); OncoMed (Inst); Pfizer (Inst); Plexxikon (Inst); Seagen (Inst); Sirtex Medical (Inst); Tokai Pharmaceuticals (Inst); TRACON Pharma (Inst) |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - G1 Therapeutics; Lilly; Pfizer; Vertex |
Research Funding - Aileron Therapeutics (Inst); AstraZeneca (Inst); Bayer (Inst); Cellceutix (Inst); Covidien (Inst); Cyclacel (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Immune Design (Inst); Lilly; Lilly (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); PTC Therapeutics (Inst); Puma Biotechnology (Inst); Sanofi (Inst); Tensha Therapeutics (Inst); Vertex (Inst) |
|
|
Consulting or Advisory Role - Lilly; Novartis; Orion |
Research Funding - Bayer; Principa Biopharma |
Travel, Accommodations, Expenses - MSD |
|
|
No Relationships to Disclose |
|
|
Employment - Lilly; Orion Health (I) |
Stock and Other Ownership Interests - Lilly |
Honoraria - Janssen (I); Sanofi (I) |
Consulting or Advisory Role - Sanofi (I) |
Speakers' Bureau - Sanofi (I) |
Travel, Accommodations, Expenses - Sanofi (I) |
|
|
|
Stock and Other Ownership Interests - Lilly |
|
|
|
|
Stock and Other Ownership Interests - Lilly |
|
|
|
Stock and Other Ownership Interests - Lilly |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Lilly |
|
|
|
|
Stock and Other Ownership Interests - Deciphera |
Patents, Royalties, Other Intellectual Property - Deciphera |
|
|
|
Stock and Other Ownership Interests - Deciphera |
Patents, Royalties, Other Intellectual Property - Deciphera |
Travel, Accommodations, Expenses - Deciphera |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Lilly |
|
|
|
Stock and Other Ownership Interests - Lilly |
Patents, Royalties, Other Intellectual Property - Cleveland Clinic |
|
|
Consulting or Advisory Role - ACI Clinical; Amgen; Biodesix; Novartis; Prometheus; Takeda; WorldCare Clinical, LLC |
Research Funding - Amgen (Inst); BioMed Valley Discoveries (Inst); Deciphera (Inst); Lilly (Inst); Merck (Inst); Roche/Genentech (Inst) |
Other Relationship - Boehringer Ingelheim |